Airway Transepithelial Transport of IgG Formulated with Excipients: A Case Study on What to Consider Regarding Impact on Epithelial Barrier Integrity, IgG Quality and Matrix Effects During the Analytics
- 1Institute of Applied Biotechnology, , Hubertus-Liebrecht Strasse 35, 88400 Biberach, Germany
Abstract
Background: Surface-active excipients such as polysorbate 20 (PS20), polysorbate 80 (PS80), poloxamer 188 (Px188), and cyclodextrin (CD) are widely used to stabilize IgG formulations, including aerosols. However, their effects on transepithelial IgG transport and the reliability of associated analytical readouts remain poorly understood. Methods: Transepithelial transport of Bevacizumab was quantified across a primary airway epithelial model in the presence of clinically relevant concentrations of PS20, PS80, Px188, or CD using ELISA. Potential methodological bias was assessed by cytotoxicity and barrier integrity (Alamar Blue, LDH, TEER), IgG monomer content (SE-HPLC), micelle formation and excipient passage, and ELISA matrix effects using excipient-containing calibration curves. Results: Only CD at 10 mg/mL significantly increased IgG transport, whereas PS20, PS80, and Px188 had no significant effect. All excipients were non-toxic, with TEER being the most sensitive indicator. IgG monomer content remained unchanged under all conditions. Micelle-forming activity of PS20, PS80, and CD was retained, but only CD (10 mg/mL) crossed the epithelial barrier (11% of the initial concentration). Excipients caused concentration-dependent ELISA matrix effects; however, matrix-adjusted quantification showed only a modest, non-significant change in calculated IgG transport for CD. Conclusions: Excipients can influence in vitro IgG transport studies through biological and analytical mechanisms. Under the tested conditions, the increased IgG transport observed with CD appears to be genuine rather than assay-related, highlighting the importance of controlling excipient-related effects in mucosal IgG transport studies.
Related
- Potentially harmful excipients in drugs: an analysis of labeling practices and adverse drug reactions
- Methodological considerations regarding the assessment of childhood fever management
- Decision-making process and support needs regarding the human papillomavirus vaccine in Japan: a qualitative interview study with mothers
- Early insights into nurses' perceptions, opportunities, and concerns regarding Ambient artificial intelligence in nursing practice
- Healthcare professionals’ knowledge, attitudes, and practices regarding perioperative ischemic stroke in elderly patients
BibTeX
@article{rittersberger2026airway,
title = {{Airway Transepithelial Transport of IgG Formulated with Excipients: A Case Study on What to Consider Regarding Impact on Epithelial Barrier Integrity, IgG Quality and Matrix Effects During the Analytics}},
author = {Rebecca Rittersberger and Gabriel Koslowski and Iman Shrimo and Katharina Schindowski},
journal = {Pharmaceutics},
year = {2026},
month = oct,
doi = {10.3390/pharmaceutics18101262},
url = {https://europepmc.org/article/PMC/PMC13708301},
note = {CC BY},
}
RIS
TY - JOUR
TI - Airway Transepithelial Transport of IgG Formulated with Excipients: A Case Study on What to Consider Regarding Impact on Epithelial Barrier Integrity, IgG Quality and Matrix Effects During the Analytics
AU - Rebecca Rittersberger
AU - Gabriel Koslowski
AU - Iman Shrimo
AU - Katharina Schindowski
PY - 2026
DA - 2026/10/01
JO - Pharmaceutics
DO - 10.3390/pharmaceutics18101262
UR - https://europepmc.org/article/PMC/PMC13708301
AB - Background: Surface-active excipients such as polysorbate 20 (PS20), polysorbate 80 (PS80), poloxamer 188 (Px188), and cyclodextrin (CD) are widely used to stabilize IgG formulations, including aerosols. However, their effects on transepithelial IgG transport and the reliability of associated analytical readouts remain poorly understood. Methods: Transepithelial transport of Bevacizumab was quantified across a primary airway epithelial model in the presence of clinically relevant concentrations of PS20, PS80, Px188, or CD using ELISA. Potential methodological bias was assessed by cytotoxicity and barrier integrity (Alamar Blue, LDH, TEER), IgG monomer content (SE-HPLC), micelle formation and excipient passage, and ELISA matrix effects using excipient-containing calibration curves. Results: Only CD at 10 mg/mL significantly increased IgG transport, whereas PS20, PS80, and Px188 had no significant effect. All excipients were non-toxic, with TEER being the most sensitive indicator. IgG monomer content remained unchanged under all conditions. Micelle-forming activity of PS20, PS80, and CD was retained, but only CD (10 mg/mL) crossed the epithelial barrier (11% of the initial concentration). Excipients caused concentration-dependent ELISA matrix effects; however, matrix-adjusted quantification showed only a modest, non-significant change in calculated IgG transport for CD. Conclusions: Excipients can influence in vitro IgG transport studies through biological and analytical mechanisms. Under the tested conditions, the increased IgG transport observed with CD appears to be genuine rather than assay-related, highlighting the importance of controlling excipient-related effects in mucosal IgG transport studies.
SN - 1999-4923
ER -